Project Grant R21MH136532
Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $450K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
- Summary: GSM-779690 Safety Demonstration Studies The University of California, San Diego received a $3.225 million Cooperative Agreement from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded August 15, 2025, with a completion date of July 31, 2027. The award funds in vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate the safety profile of GSM-779690, a small-molecule gamma-secretase modulator being developed as a...
- Grant Award Summary Alphamemory, LLC received a Phase I Small Business Technology Transfer (STTR) award of $504,248 from the National Institute on Aging under the Aging Research program (CFDA 93.866) on September 20, 2025. The award supports drug discovery research targeting the transmembrane domain of the amyloid precursor protein (APP) as an alternative approach to reduce amyloid production in Alzheimer's disease. This research strategy addresses limitations of previous gamma-secretase...
- This federal Project Grant award of $647,833 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), supports research conducted by Northwestern University to investigate cellular mechanisms underlying excitation/inhibition imbalance in the medial prefrontal cortex as a convergent pathogenic mechanism across genetic mouse models relevant to schizophrenia. The key research objectives are to: 1) determine the reversal potential of the...
- This federal Project Grant award from the National Institute of Mental Health (CFDA 93.242 Mental Health Research Grants) provides $460,855 to New York University School of Medicine to investigate the cellular and circuit mechanisms by which acetylcholine (ACh) promotes associative learning in the primary somatosensory cortex. The key objectives are to: 1) use fluorescent ACh sensors and chemogenetic techniques to study the magnitude and time course of ACh release during different phases of an...
- Summary: Neurophysiological Correlates of Cognition Over Multi-Day Timescales in Epilepsy The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital $234,630 on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct a five-year prospective research study examining the neurophysiological basis of cognitive impairment in temporal lobe epilepsy (TLE). The research...
- This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $429,000.00 in funding to Thomas Jefferson University to conduct research on cell-type specific analysis of Src kinase-NMDA receptor complexes in schizophrenia. The goal of this 2-year project is to determine how Src kinase-mediated NMDA receptor signaling alterations are distinctly manifested in pyramidal neurons versus interneurons in the...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $388,158.00 to the University of California, Los Angeles (UCLA) to engineer a highly active and selective gamma-Aminobutyric Acid (GABA) oxidase enzyme. The goal is to develop a high-performance, implantable, electroenzymatic GABA microsensor that can monitor GABA transients in the...
- Federal Project Grant Award Summary Psychogenics Inc. received a $495,699 project grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 20, 2025, with completion targeted for September 19, 2027. The project focuses on the development and preclinical evaluation of PGI-5128, a novel drug candidate designed to treat agitation and aggression in Alzheimer's disease patients. Phase I deliverables include efficacy studies of PGI-5128 in...
- Federal Cooperative Agreement Summary Weill Medical College of Cornell University received a $3.25 million Cooperative Agreement from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded April 1, 2026, with completion targeted for March 31, 2028. The agreement funds a Phase 1A clinical safety and dose-ranging trial of AAVRH.10HAPOE2CH, a novel gene therapy vector designed to treat Apolipoprotein E4 (APOE4) homozygous Alzheimer's disease. The therapeutic...
- This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...